How to Conduct Post-Market Surveillance for Overseas Registration of Imaging Equipment?

How to Conduct Post-Market Surveillance for Overseas Registration of Imaging Equipment?

Published: 2026-08-13 17:08 | Updated: 2026-08-13 17:08

This article addresses key issues that medical device companies need to prioritize in real projects regarding international registration, documentation preparation, compliance pathways, and post-market maintenance.

Content Structure

• Key Summary
• Applicable Scenarios and Core Issues
• Registration Decision Logic
• Documentation and Evidence
• Common Mistakes
• Preparation Checklist for Enterprises
• AIMEILI Insights
• Frequently Asked Questions
• Continue Reading
• Content Review and Applicability

Key Summary

After completing overseas registration for imaging equipment, companies often mistakenly believe that obtaining the registration certificate fulfills compliance. In reality, post-market surveillance is the key to sustained compliance. Companies must first confirm whether the product falls under the medical device regulatory scope in the target country, and then determine the registration pathway and applicant entity based on the risk classification. Regardless of whether the target market is a GHWP member state or a country in Southeast Asia, the Middle East, or Latin America, technical documentation, risk management, clinical evidence, and quality systems are the foundation of registration review. However, labeling, instructions for use, local agent authorization, and adverse event reporting requirements must be re-interpreted according to local regulations. Companies should establish post-market surveillance processes for overseas markets, including assessment of registration impact for product changes, management of certificate validity, annual reporting or renewal obligations, liaison with vigilance systems, and communication mechanisms with local agents. Common risks include registration certificate invalidation due to unassessed changes, labeling not meeting local language requirements, failure to report adverse events in a timely manner, and loss of control over the certificate due to improper agent selection. Before marketing, companies should first review the reusability of existing NMPA, CE, FDA, or ISO 13485 documentation, identify documents that need localization, clarify the responsibilities of all parties, and develop a coordinated update plan for multi-country registrations. This approach reduces the risk of deficiencies while maintaining the validity of registration certificates. (Compiled based on the AIMEILI Registration Practice Question Bank, the Medical Device International Registration Knowledge Base, and public regulatory information. Specific projects should be based on the latest requirements of the target country's competent authority and the foundation of product documentation.)

Applicable Scenarios and Core Issues

After completing overseas registration, imaging device companies typically face ongoing tasks such as product upgrades, software version changes, labeling updates, adverse event collection, and certificate maintenance upon expiry. Post-market surveillance is not an additional task independent of registration, but a compliance status that must be maintained throughout the validity of the registration certificate.

This article applies to manufacturers of imaging equipment that have obtained or plan to apply for registration in GHWP member states, Southeast Asia, the Middle East, or Latin America, including active imaging equipment such as X-ray, ultrasound, CT, MRI, and endoscopes. The core question is: after obtaining the registration certificate, what should the enterprise do and how, to avoid suspension or withdrawal of registration due to insufficient oversight?

Companies need to break down post-market surveillance into four modules: document maintenance, change control, adverse events, and certificate management. Each module requires clear responsible persons and execution frequency. If these processes are not established in advance, systemic deficiencies often surface during deficiency corrections, renewals, or unannounced inspections.

Registration Decision Logic

The first step is to determine whether the target country regulates imaging equipment as medical devices. Different countries may classify certain imaging equipment as medical devices, may separately classify some software as medical devices, or may subject them to additional regulation as radiation equipment. Companies should confirm the regulatory scope during the project initiation phase, rather than discovering a mismatch at the time of submission.

The second step is to determine the product's risk classification. Imaging equipment is usually medium or high risk, but the specific classification may vary based on imaging principles, patient contact, and whether diagnostic results are provided. The risk classification directly determines the registration pathway, review timeline, and depth of technical documentation. Companies cannot directly copy domestic classifications; they must confirm the classification result on a country-by-country basis.

The third step is to determine the applicant entity. Most countries require a local registration holder or license holder to assume application and post-market responsibilities, and some countries also require the designation of a local agent or authorized representative. The relationship between the applicant entity and the agent directly affects certificate ownership, the method of submitting changes, and the adverse event reporting pathway.

The fourth step is to assess the reusability of existing documentation. If the company already holds an NMPA registration certificate, CE certificate, FDA 510(k) or PMA, ISO 13485 or MDSAP certification, it should use the registration certificate, technical documents, risk management reports, clinical evaluation data, test reports, and quality management system certificates as a base package, and then perform a gap analysis according to the target country's requirements. Reusable parts include basic product performance testing, electrical safety testing, electromagnetic compatibility testing, and quality system documents. However, clinical evaluation, labeling and instructions for use, software verification, and certain biological evaluations may require localization or supplementation.

The fifth step is to comprehensively confirm post-market obligations, including whether product changes require notification or approval, annual update or periodic reporting requirements, adverse event reporting timelines, recall reporting, obligations to cooperate with on-site inspections, and certificate renewal processes. The post-market surveillance plan should be designed based on these obligations.

Documentation and Evidence

The documentation to be prepared and maintained for post-market surveillance can be divided into six categories. The first category is core registration documents, including product standards, technical documentation, risk management files, clinical evaluation or clinical evidence, software descriptions, and cybersecurity documentation. These documents form the backbone of registration review and serve as the baseline for change assessment.

The second category is quality system evidence, including ISO 13485 or MDSAP certificates, internal audit reports, management review records, supplier management records, and design change records. The quality system is the core of post-market inspections in many countries; system records demonstrate that the company continues to produce in accordance with regulations.

The third category is labeling and instructions for use, including labels in the target country's language, instructions for use, quick reference guides, and package marking. Label content must be consistent with registration documents, and any changes should be documented and assessed to determine whether registration information needs to be updated.

The fourth category is localization and agent documentation, including local agent agreements, letters of authorization, agent qualification documents, and communication records with the agent. Agent changes, agent termination, or unclear authorization scope can interrupt registration maintenance.

The fifth category is post-market surveillance data, including adverse event reports, complaint records, user feedback, literature reports, and clinical safety updates. This evidence is used for annual updates, risk re-evaluation, and periodic safety update reports.

The sixth category is certificate management records, including copies of registration certificates, a list of validity periods, renewal plans, change approval records, and payment records. Once a certificate expires, the cost of re-registration is far higher than renewing on time.

Companies should establish document control procedures to ensure that each version of documentation has a unique number, version number, and effective date. During deficiency corrections and on-site inspections, reviewers most often challenge the inability to trace between different versions.

Common Mistakes

• Treating the registration certificate as a permanent qualification, ignoring the certificate's validity period and local annual maintenance requirements, resulting in forced re-registration after the certificate expires.
• When software updates, hardware modifications, or intended use changes occur, failing to first assess the registration impact and directly selling the changed product, leading to a determination that the product does not conform to the registered content.
• Producing labels and instructions for use only in English, not updating them to meet the target country's language requirements, or having the design rejected at customs or penalized in spot checks due to non-compliance with local regulations.
• After appointing a local agent, failing to provide the agent with complete technical documentation and communication support, so the agent cannot answer questions from regulators, delaying deficiency corrections and adverse event reporting.
• Inconsistent adverse event handling processes with local requirements, such as incorrect calculation of reporting timelines, incorrect severity classification, or omission of reports, leading to warning letters.
• Using a single set of documents for multi-country registration while ignoring differences in clinical data, software classification, and testing standards among countries, leading to repeated deficiency corrections.
• Incomplete post-market surveillance records that fail to demonstrate the logical relationship among design changes, risk management updates, and complaint handling, resulting in loss of points during unannounced inspections.

Preparation Checklist for Enterprises

• Establish a list of medical device regulatory scopes for target countries, confirming the classification and registration pathway for each imaging device.
• Review existing NMPA, CE, FDA, ISO 13485, and MDSAP certificates and documentation to form a reusable document list.
• Designate a registration person-in-charge and a local agent for each target market, clarifying authorities and responsibilities in written agreements.
• Develop a localization plan for labels and instructions for use, confirming language requirements, symbol usage, and expiration date labeling standards.
• Establish a product change control process, distinguishing between change categories that require notification, filing, or approval.
• Design processes for adverse event receipt, evaluation, reporting, and tracking, and conduct drills against each country's timelines.
• Develop a ledger of certificate validity periods and a renewal plan, starting renewal preparation at least 6-12 months in advance.
• Establish archiving standards for post-market surveillance documents to ensure traceability of registration, change, complaint, and agent communication records.

AIMEILI Insights

The most common misjudgment by imaging device companies is treating pre-registration technical work as a one-time investment, while ignoring the cross-departmental collaboration required for post-market surveillance. In fact, post-registration document maintenance, change assessment, and adverse event reporting require the joint participation of regulatory, R&D, quality, after-sales, and agents. Interruption of any one link may affect the certificate.

In the early stage of a project, it is recommended to first complete a 'registration baseline audit,' organizing existing registration certificates, test reports, risk management documentation, and clinical evidence into a reusable core data repository in a common format. This repository serves as the common basis for all target markets and the basis for subsequent deficiency corrections and change assessments.

Reusable documentation includes product hardware specifications, electrical safety testing, EMC reports, some software verification, and ISO 13485 quality system evidence. Documentation that must be localized includes labels in the target country's language, instructions for use, analysis of local clinical usage habits, local agent agreements, and post-market surveillance documents that comply with local regulations. Companies can manage multi-country registrations using a 'common package + country-specific package' structure.

A local agent is not merely a procedural handler, but the formal communication window between the regulatory authority and the company. The company should ensure that the agent has access to complete technical documentation and is authorized to submit changes and receive inspection notices on its behalf. Certificate control is also a key issue; it is recommended that the company hold certificate ownership, with the agent only assuming liaison obligations within a specified scope.

A common pain point in multi-country registration is repeated document preparation and repeated deficiency corrections. Companies should modularize registration documents, reuse GMP and safety testing portions, and supplement only clinical evaluations and country-specific requirements. At the same time, establish a central change assessment ledger so that one change triggers impact assessments across multiple countries simultaneously, avoiding divergence among country versions.

Frequently Asked Questions

Q: If a software version update occurs, is it mandatory to notify the country of registration?

A: It is necessary to first determine whether the update affects product safety, effectiveness, or intended use. General defect fixes usually do not require notification, but functional additions, algorithm changes, updates involving diagnostic judgment, or significant user interface adjustments may constitute changes that require assessment. It is recommended that companies establish a tiered assessment table, evaluate each item against the target country's change guidelines, and consult with the regulatory authority via the local agent when necessary.

Q: What key clauses should a local agent agreement include?

A: The agreement should specify the scope of services, access to documentation, authorization boundaries for submitting changes, adverse event reporting responsibilities, obligations to cooperate with inspections, renewal and fee arrangements, and transition responsibilities upon contract termination. It should also establish training and evaluation mechanisms for the agent to ensure that the agent can accurately convey the regulatory authority's deficiency opinions.

Continue Reading

• Previous: What Are Common Reasons for Deficiency Corrections in Overseas Registration of Imaging Equipment?
• Next: When Should Registration Changes Be Submitted for Overseas Registration of Imaging Equipment?

Recommended Reading:

• How to Conduct Post-Market Surveillance for Overseas Registration of Active Medical Devices?
• Can Test Reports Be Reused for Overseas Registration of Imaging Equipment?
• How to Choose a Local Agent for Overseas Registration of Imaging Equipment?
• What Are Common Reasons for Deficiency Corrections in Overseas Registration of Imaging Equipment?
• When Should Registration Changes Be Submitted for Overseas Registration of Imaging Equipment?
• How to Group Multiple Models for Submission in Overseas Registration of Imaging Equipment?
• Return to FAQ Center

Content Review and Applicability

Content Author: AIMEILI Regulatory Editorial Department

Professional Review: AIMEILI Medical Device International Registration Project Team

Source Principles: Priority is given to official regulatory authorities, international organizations, standards organizations, and publicly available regulatory information; industry media and project experience are used only as supplementary judgment.

Applicability: This article is intended for preliminary understanding, documentation preparation, and project planning, and does not replace formal requirements, test conclusions, or legal opinions from the target country's regulatory authority.